Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Annals of Hematology

25-04-2024 | Daratumumab | Research

Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study

Authors: Hui Shi, Fan Yang, Miaomiao Cao, Teng Xu, Peihao Zheng, Yuelu Guo, Guoai Su, Shaomei Feng, Ruiting Li, Rui Liu, Haidi Liu, Lixia Ma, Xiaoyan Ke, Kai Hu

Published in: Annals of Hematology

Login to get access

Abstract

The prognosis of patients diagnosed with relapsed or refractory (R/R) T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) has consistently been unsatisfactory, with limited treatment options. As reports, the CAG regimen can serve as a salvage treatment for R/R T-ALL/LBL, but there remains a subset of patients who do not benefit from it. Recent studies have indicated that daratumumab (Dara) and venetoclax (Ven) may offer promising therapeutic benefits for T-ALL/LBL. In light of these findings, we conducted a safety and efficacy evaluation of the enhanced treatment regimen, combining Dara and Ven with aclarubicin, cytarabine, granulocyte colony-stimulating factor, and etoposide (CAGE), in patients suffering from R/R T-ALL/LBL. The participants in this phase I trial were patients with R/R T-ALL/LBL who fail to standard treatment regimens. During each 28-day cycle, the patients were treated by Dara, Ven, cytarabine, aclarubicin, granulocyte colony-stimulating factor, etoposide. The primary endpoint of this study was the rate of remission. This report presents the prospective outcomes of 21 patients who received the salvage therapy of Dara and Ven combined with the CAGE regimen (Dara + Ven + CAGE). The objective remission rate (ORR) was determined to be 57.1%, while the complete remission (CR) rate was 47.6%. Notably, patients with the early T-cell precursor (ETP) subtype exhibited a significantly higher remission rate in the bone marrow compared to non-ETP patients (100% vs. 44.4%, p = 0.044). The Dara + Ven + CAGE regimen demonstrated a favorable remission rate in patients with R/R T-ALL/LBL. Moreover, the treatment was well-tolerated.
Appendix
Available only for authorised users
Literature
1.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951CrossRefPubMed
2.
Patte C, Kalifa C, Flamant F, Hartmann O, Brugières L et al (1992) Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol 20:105–113CrossRefPubMed
3.
Gross TG, Hale GA, He W, Camitta BM, Sanders JE et al (2010) Hematopoietic stem cell transplantation for refractory or recurrent non-hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transpl 16:223–230CrossRef
4.
Mitsui T, Mori T, Fujita N, Inada H, Horibe K, Tsurusawa M (2009) Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan. Pediatr Blood Cancer 52:591–595CrossRefPubMed
5.
Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR et al (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109:944–950CrossRefPubMed
6.
Pan J, Tan Y, Wang G, Deng B, Ling Z et al (2021) Donor-derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: first-in-Human, phase I Trial. J Clin Oncol 39:3340–3351CrossRefPubMed
7.
Lu P, Liu Y, Yang J, Zhang X, Yang X et al (2022) Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial. Blood 140:321–334PubMed
8.
Specchia G, Pastore D, Carluccio P, Liso A, Mestice A et al (2005) FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Ann Hematol 84:792–795CrossRefPubMed
9.
Hijiya N, Thomson B, Isakoff MS, Silverman LB, Steinherz PG et al (2011) Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 118:6043–6049CrossRefPubMedPubMedCentral
10.
Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A et al (2005) Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J Clin Oncol 23:3376–3382CrossRefPubMed
11.
Gökbuget N, Basara N, Baurmann H, Beck J, Brüggemann M et al (2011) High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood 118:3504–3511CrossRefPubMed
12.
Qian JJ, Hu X, Wang Y, Zhang Y, Du J et al (2020) CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: a retrospective, multicenter, cohort study. Cancer Med 9:5327–5334CrossRefPubMedPubMedCentral
13.
Xue SL, Wu DP, Sun AN, Tang XW (2008) CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases. Am J Hematol 83:167–170CrossRefPubMed
14.
Cerrano M, Castella B, Lia G, Olivi M, Faraci DG et al (2020) Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia. Br J Haematol 191:e28–e32CrossRefPubMed
15.
Ruhayel SD, Valvi S (2021) Daratumumab in T-cell acute lymphoblastic leukaemia: a case report and review of the literature. Pediatr Blood Cancer 68:e28829CrossRefPubMed
16.
Mirgh S, Ahmed R, Agrawal N, Khushoo V, Garg A et al (2019) Will Daratumumab be the next game changer in early thymic precursor-acute lymphoblastic leukaemia? Br J Haematol 187:e33–e5CrossRefPubMed
17.
DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:7–17CrossRefPubMedPubMedCentral
18.
Zappone E, Cencini E, Defina M, Sicuranza A, Gozzetti A et al (2020) Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia. Clin Case Rep 8:2000–2002CrossRefPubMedPubMedCentral
19.
McEwan A, Pitiyarachchi O, Viiala N (2020) Relapsed/Refractory ETP-ALL successfully treated with Venetoclax and Nelarabine as a bridge to allogeneic stem cell transplant. Hemasphere 4:e379CrossRefPubMedPubMedCentral
20.
La Starza R, Cambò B, Pierini A, Bornhauser B, Montanaro A et al (2019) Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia. JCO Precis Oncol 3
21.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Version 1.2022 Acute Lymphoblastic Leukemia. (2022) https://​www.​nccn.​org
22.
23.
O’Dwyer KM (2022) Optimal approach to T-cell ALL. Hematol Am Soc Hematol Educ Program 2022:197–205CrossRef
24.
McKeage K, Lyseng-Williamson KA (2016) Daratumumab in multiple myeloma: a guide to its use as monotherapy in the EU. Drugs Therapy Perspect 32:463–469CrossRef
25.
Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM et al (2018) Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood 131:995–999CrossRefPubMedPubMedCentral
26.
Bras AE, Beishuizen A, Langerak AW, Jongen-Lavrencic M, Te Marvelde JG et al (2018) CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy. Br J Haematol 180:292–296CrossRefPubMed
27.
Tembhare PR, Sriram H, Khanka T, Chatterjee G, Panda D et al (2020) Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy. J Immunother Cancer 8
28.
Vogiatzi F, Winterberg D, Lenk L, Buchmann S, Cario G et al (2019) Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia. Blood 134:713–716CrossRefPubMed
29.
Ofran Y, Ringelstein-Harlev S, Slouzkey I, Zuckerman T, Yehudai-Ofir D et al (2020) Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia. Leukemia 34:293–295CrossRefPubMed
30.
Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K et al (2014) ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood 124:3738–3747CrossRefPubMed
31.
Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM et al (2020) Clinical experience with Venetoclax Combined with Chemotherapy for relapsed or refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20:212–218CrossRefPubMed
32.
Stanulla M, Schewe DM, Bornhauser B, Bourquin JP, Eckert C et al (2023) Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia. Ann Hematol 102:669–672CrossRefPubMedPubMedCentral
33.
Yang F, Li Z, Dong C, Lei Y, Geng Y et al (2020) Daratumumab and Venetoclax-Containing regimens in the management of Relapse after Allogeneic hematopoietic stem cell transplantation in hematological malignancies. Blood 136:9
34.
Voruz S, Blum S, de Leval L, Schoumans J, Solly F, Spertini O (2021) Daratumumab and Venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript. Biomark Res 9:92CrossRefPubMedPubMedCentral
35.
Vogiatzi F, Heymann J, Müller K, Winterberg D, Drakul A et al (2022) Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis. Blood Adv 6:4847–4858CrossRefPubMedPubMedCentral
36.
Lepretre S, Graux C, Touzart A, Macintyre E, Boissel N (2017) Adult T-type lymphoblastic lymphoma: treatment advances and prognostic indicators. Exp Hematol 51:7–16CrossRefPubMed
37.
Jain N, Lamb AV, O’Brien S, Ravandi F, Konopleva M et al (2016) Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood 127:1863–1869CrossRefPubMedPubMedCentral
38.
Chen W, Shi H, Liu Z, Yang F, Liu J et al (2023) Single-cell Transcriptomics reveals Immune reconstitution in patients with R/R T-ALL/LBL treated with donor-derived CD7 CAR-T therapy. Clin Cancer Res 29:1484–1495CrossRefPubMed
Metadata
Title
Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study
Authors
Hui Shi
Fan Yang
Miaomiao Cao
Teng Xu
Peihao Zheng
Yuelu Guo
Guoai Su
Shaomei Feng
Ruiting Li
Rui Liu
Haidi Liu
Lixia Ma
Xiaoyan Ke
Kai Hu
Publication date
25-04-2024
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-05775-z
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits